1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Breast cancer is the most frequently diagnosed malignancy in women worldwide and the leading cancer among Indonesian women. Approximately 15-20% of invasive breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2), a transmembrane tyrosine-kinase receptor whose gene amplification drives uncontrolled proliferation and confers an aggressive natural history with higher recurrence and historically shorter survival than HER2-negative disease in the absence of targeted therapy (Slamon et al., NEJM 2001). HER2 status is determined by immunohistochemistry (IHC 0/1+ negative, 3+ positive), with equivocal 2+ tumours reflexed to in-situ hybridisation (FISH). HER2-positive disease spans early-stage (operable), locally advanced, and metastatic presentations. Trastuzumab (ATC L01FD01), a recombinant humanised anti-HER2 monoclonal antibody, binds the receptor's extracellular domain, inhibiting downstream signalling and recruiting antibody-dependent cell-mediated cytotoxicity. It was the first agent to translate this biomarker into targeted therapy, transforming HER2-positivity from an adverse prognostic marker into a predictive marker of treatment benefit and establishing HER2 status as a mandatory companion diagnostic guiding therapy selection across all stages.
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
Globally, GLOBOCAN 2022 estimated approximately 2.3 million new female breast cancer cases and 670,000 deaths, making it the most commonly diagnosed cancer in women across the majority of countries (IARC GLOBOCAN 2022). In Indonesia, breast cancer is the single most common cancer with an estimated 66,271 new cases in 2022 (ahead of lung 38,904 and cervix uteri 36,964; 22,598 breast cancer deaths), within a national total of roughly 408,661 cancer cases and 242,099 deaths (GLOBOCAN 2022, Indonesia fact sheet). National projections anticipate continued growth, with total cancer cases rising about 63% between 2025 and 2040. HER2-positive disease constitutes an estimated 20-25% of Indonesian breast cancers; population-level series vary, with a Central Java IHC series reporting the HER2-overexpressing subtype at about 20.2% (associated with larger tumours, nodal metastasis, and poorer grade; Widodo et al., 2014), while hospital case series report higher HER2 positivity (e.g., Dharmais Cancer Centre ~45%; ~30.6% in young patients). Critically, Indonesian patients frequently present at advanced stage: in hospital cohorts only ~36% were early stage, ~48% locally advanced, and ~16% metastatic, with roughly 20% diagnosed already metastatic in registry data, owing to substantial diagnostic and referral delays (Sinaga et al., 2023; Anwar et al., 2022).
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
Trastuzumab combined with chemotherapy is the global standard of care for HER2-positive breast cancer and the comparator-defining therapy against chemotherapy alone. In early disease, anti-HER2 therapy with trastuzumab is added to (neo)adjuvant anthracycline/taxane chemotherapy, typically for one year, alongside surgery and, where indicated, radiotherapy and endocrine therapy; two years of trastuzumab confers no additional benefit (HERA; Cameron et al., Lancet 2017), and dual blockade with pertuzumab is used in high-risk node-positive disease. In metastatic disease, first-line standard is dual HER2 blockade with pertuzumab plus trastuzumab plus a taxane, with trastuzumab emtansine and trastuzumab deruxtecan in later lines (NICE TA509; ESMO/NCCN guidelines). The comparator anchoring this appraisal is chemotherapy alone without anti-HER2 therapy, the pre-trastuzumab standard now considered substandard for HER2-positive tumours. Treatment requires baseline and periodic cardiac monitoring (LVEF) given cardiotoxicity risk. In Indonesia, trastuzumab plus chemotherapy is delivered through tertiary oncology centres and has been listed in the national formulary (Fornas) since 2014, supporting use within the JKN/BPJS Kesehatan benefit package, with originator and biosimilar products now available at broadly comparable prices.
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
Trastuzumab (Herceptin) received US FDA approval in 1998 for HER2-overexpressing metastatic breast cancer and EMA marketing authorisation in 2000, with subsequent extension to adjuvant early breast cancer; multiple biosimilars have since been approved by both FDA and EMA. NICE recommends trastuzumab-containing regimens for HER2-positive early and advanced disease, with TA107 covering adjuvant treatment of early HER2-positive breast cancer and TA509 (2018) covering pertuzumab plus trastuzumab and docetaxel for HER2-positive metastatic breast cancer. In Indonesia, trastuzumab is registered with BPOM and has been included in Fornas since 2014; following InaHTAC review the originator was excluded from the formulary in 2018 (use lay dormant 2017-2019), then reinstated in 2020 as biosimilars became available, with originator and biosimilar prices converging to broadly comparable levels (price parity) by 2021 (Setiawan et al., Health Systems & Reform 2024). It is reimbursed under the JKN national health insurance scheme administered by BPJS Kesehatan within defined clinical criteria, making HER2 testing and oncology referral central to access. This contested appraisal history is a documented example of InaHTAC using HTA to influence national medicine pricing and access decisions, with the originator's utilisation rising to 1,292 tablets after 2020 reinstatement before declining to 807 tablets amid biosimilar price parity in 2021.
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Trastuzumab adjuvan selama satu tahun ditambah kemoterapi | Rp 689,7 juta | 10,105 | 19,84 |
| kemoterapi standar tanpa terapi anti-HER2 | Rp 491,0 juta | 8,295 | 15,22 |
| Selisih | Rp 198,7 juta | 1,811 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (50 yr) | 1,811 | Rp 198,7 juta | Rp 109,7 juta |
| 5-year horizon | 0,085 | Rp 97,1 juta | Rp 1,1 miliar |
| 10-year horizon | 0,377 | Rp 108,0 juta | Rp 286,6 juta |
| 20-year horizon | 1,085 | Rp 148,5 juta | Rp 136,9 juta |
| 0% discount rate | 3,378 | Rp 303,5 juta | Rp 89,8 juta |
| 5% discount rate | 1,269 | Rp 163,0 juta | Rp 128,4 juta |
| Biosimilar trastuzumab at 50% of base price | 1,811 | Rp 150,2 juta | Rp 83,0 juta |
| Higher baseline recurrence (late-stage Indonesian presentation, metastasis rate x1.3) | 1,729 | Rp 198,6 juta | Rp 114,9 juta |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| Annual locoregional recurrence rate, disease-free state (chemotherapy-alone arm) | 2,9% | 2,9% | Khoirunnisa 2024 PLOS One Indonesia HER2+ early breast cancer model: disease-free to locoregional recurrence 0.029/yr (H |
| Annual distant-metastasis rate, disease-free state (chemotherapy-alone arm) | 7,8% | 7,8% | Khoirunnisa 2024 PLOS One: disease-free to metastasis 0.078/yr (HERA-based, chemotherapy-alone arm). |
| Cumulative all-cause mortality at 10 years (chemotherapy-alone arm) | 33,7% | 37,0% | HERA observation arm: 10-year disease-free survival 63%, 12-year overall survival 73% (Cameron et al., Lancet 2017). ~10 |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- NICE recommends trastuzumab-containing regimens for HER2-positive early (TA107) and advanced (TA509) breast cancer; the published directional conclusion is cost-effective/recommended.
- An Indonesia-specific CEA (Khoirunnisa 2024) found adjuvant trastuzumab cost-effective at the 3x GDP-per-capita threshold (ICER US$6,842/QALY; ~Rp105M/QALY), most favourable in women under 40; this engine reproduces that model with the engine's threshold convention.
- Trastuzumab is listed in Fornas (since 2014; delisted 2018, reinstated 2020) and reimbursed under JKN; originator and biosimilar prices have converged (price parity by 2021).
- Budget impact is material because breast cancer is Indonesia's leading female cancer (66,271 cases, 2022 GLOBOCAN) and ~20-25% are HER2-positive; the eligible adjuvant population is large and the drug cost is concentrated in a single treatment year.
- Equity: late-stage presentation and uneven HER2 testing capacity outside Java-Bali limit real-world access; reliable IHC/ISH companion diagnostics are a precondition for appropriate use.